Inventiva FIRST LOOK: Raising up to € 348m in multi-tranche equity financing
Inventiva raises up to € 348m in a multi-tranche equity financing, of which € 94.1m gross proceeds upfront. The first tranche extends Inventiva's runway into 2Q25, and if all tranches are triggered, would fully support the company's Phase 3 NATiV3 trial and commercial launch for lanifibranor. With the backing of a strong international investor syndicate, the transaction thereby largely resolves IVA's financing overhang in our view.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.